Oxonol vs MIT vs 7-OH: Product Identity Guide

Oxonol, MGM-15, 7-OH, and MIT can appear in the same retail conversation, but they do not identify the same thing. Start with the product’s ingredient line, then connect that identity to a dated regulatory source.

The most important difference: brand name versus substance name

Oxonol is the manufacturer’s brand name for a product it describes as containing MGM-15 and mitragynine. MGM-15 is the substance name that appears in DEA’s July 2026 notice. A retail name does not remove a named ingredient from the scope of a document that addresses that ingredient.

Oxonol vs 7-OH

Oxonol is not simply another spelling of 7-OH. Its manufacturer describes MGM-15 as part of the formula, while DEA identifies MGM-15 as dihydro-7-hydroxymitragynine, a derivative of 7-hydroxymitragynine. DEA addressed elevated 7-OH in one July 2026 notice and MGM-15, MGM-16, and mitragynine pseudoindoxyl in another. Both notices must be read on their own terms.

The FDA also distinguishes naturally occurring trace 7-OH in botanical material from unlawful products sold with high concentrations of 7-OH. Its consumer update states that there are no FDA-approved products containing 7-OH. That is not a statement that every product using a different brand name is approved or unaffected.

Oxonol vs MIT

MIT means mitragynine. It is a naturally occurring kratom alkaloid and is not the same compound as MGM-15. MIT tablets and powders can concentrate mitragynine, so the label still needs a clear percentage or milligram basis, package count or net weight, and relevant documentation. The advantage of the MIT lane is clarity: one can identify the named alkaloid, select a tablet or powder form, preserve the original units, and review the stated document scope without treating the product as an MGM-series formulation.

Kratom Paradise’s MIT catalog does not present its products as Oxonol, MGM-15, 7-OH, a therapeutic substitute, or an equivalent experience. For shoppers prioritizing a distinct ingredient identity, familiar tablet or powder formats, and qualified source-material documentation, the MIT catalog is the more straightforward comparison path.

Form factor does not establish chemical identity

Oxonol products and MIT products may both appear as chewable tablets. A gummy, shot, tablet, capsule, or powder describes physical form; it does not tell you which alkaloid is present. Two chewable tablets can have entirely different named ingredients and regulatory questions. Compare the ingredient line before comparing flavor, count, or convenience.

What to compare before choosing a product lane

• Identity: Is the label MIT, MGM-15, 7-OH, pseudoindoxyl, a blend, or only a branded phrase?
• Disclosure: Are the active ingredients and their basis stated plainly?
• Documents: Does a report cover source material or the finished product, and does the sample match?
• Status: Is the legal statement tied to the current federal, state, and local record?
• Format: Does the package provide a tablet count, net weight, and consistent selector fields?

Current bottom line

As of July 14, 2026, DEA has published notices of intent, and the MGM-15 temporary order is not yet effective. The notice says an order cannot be issued before August 5, 2026. Because the manufacturer identifies MGM-15 in Oxonol, the MGM-15 notice is directly relevant to current Oxonol comparisons. MIT remains a separate named alkaloid and product category; its status should still be checked against the buyer’s jurisdiction and the actual product record.

Continue with the Oxonol and MGM-15 guide, 7-OH vs kratom vs MIT comparison, or MIT chewable tablet collection.

This comparison is educational product and regulatory information, not medical or legal advice.